FibroGen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1993-01-01

Employees: 486

Market Cap: $38.6M

Website: http://www.fibrogen.com

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Phase 3

Completed

Conditions: Chemotherapy Induced Anemia

Interventions: Drug: SEPO®
Drug: Roxadustat

First Posted Date: 2022-03-29

Last Posted Date: 2023-06-06

Lead Sponsor: FibroGen

Target Recruit Count: 159

Registration Number: NCT05301517

Locations: 🇨🇳
Shandong First Medical University Cancer Hospital, Jinan, China
🇨🇳
The Second Hospital of Lanzhou University, Lanzhou, China
🇨🇳
Neijiang Second People's Hospital, Neijiang, China

and more 42 locations

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

Phase 3

Terminated

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Pamrevlumab
Drug: Placebo
Drug: Corticosteroids

First Posted Date: 2020-11-17

Last Posted Date: 2024-08-26

Lead Sponsor: FibroGen

Target Recruit Count: 73

Registration Number: NCT04632940

Locations: 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
University of California San Diego Health, San Diego, California, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 49 locations

Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

Phase 3

Withdrawn

Conditions: Anemia Associated With Chronic Kidney Disease

Interventions: Drug: Roxadustat

First Posted Date: 2020-11-09

Last Posted Date: 2022-07-05

Lead Sponsor: FibroGen

Registration Number: NCT04621331

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York, New York, United States

and more 1 locations

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

Phase 3

Completed

Conditions: Anemia Associated With End Stage Renal Disease

Interventions: Drug: Roxadustat

First Posted Date: 2020-07-24

Last Posted Date: 2022-07-26

Lead Sponsor: FibroGen

Target Recruit Count: 283

Registration Number: NCT04484857

Locations: 🇺🇸
Investigational Site, Norfolk, Virginia, United States
🇺🇸
Investigator Site, San Antonio, Texas, United States
🇺🇸
Investigator Sites, San Antonio, Texas, United States

and more 1 locations

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: Pamrevlumab

First Posted Date: 2020-06-16

Last Posted Date: 2022-07-18

Lead Sponsor: FibroGen

Target Recruit Count: 22

Registration Number: NCT04432298

Locations: 🇺🇸
Research Center, Philadelphia, Pennsylvania, United States

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 3

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: Pamrevlumab

First Posted Date: 2020-06-05

Last Posted Date: 2024-08-12

Lead Sponsor: FibroGen

Target Recruit Count: 372

Registration Number: NCT04419558

Locations: 🇳🇱
Longarts - Opleider Longziekten Zuyderland MC, Heerlen, Netherlands
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇬🇧
University College London, London, United Kingdom

and more 154 locations

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

Phase 3

Completed

Conditions: Anemia Associated With End Stage Renal Disease (ESRD)

Interventions: Drug: Roxadustat

First Posted Date: 2020-06-01

Last Posted Date: 2022-09-13

Lead Sponsor: FibroGen

Target Recruit Count: 203

Registration Number: NCT04410198

Locations: 🇺🇸
Investigational Site, Saint George, Utah, United States

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Phase 3

Terminated

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Placebo
Drug: Pamrevlumab
Drug: Corticosteroids

First Posted Date: 2020-05-01

Last Posted Date: 2024-03-12

Lead Sponsor: FibroGen

Target Recruit Count: 98

Registration Number: NCT04371666

Locations: 🇺🇸
Rare Disease Research, LLC, Atlanta, Georgia, United States
🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 50 locations

Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Phase 2

Completed

Conditions: Chemotherapy Induced Anemia

Interventions: Drug: Roxadustat

First Posted Date: 2019-09-04

Last Posted Date: 2022-06-03

Lead Sponsor: FibroGen

Target Recruit Count: 92

Registration Number: NCT04076943

Locations: 🇺🇸
Research Center, Philadelphia, Pennsylvania, United States

Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease

Phase 4

Completed

Conditions: CKD Anemia in Dialysis Participants

Interventions: Drug: Roxadustat

First Posted Date: 2019-08-16

Last Posted Date: 2022-05-06

Lead Sponsor: FibroGen

Target Recruit Count: 318

Registration Number: NCT04059913

Locations: 🇨🇳
Investigational Site, Tianjin, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy